Skip to main content
Traducción en proceso — este contenido se muestra en inglés mientras se prepara la versión en su idioma.
Volver a Discusiones

How could using smarter, real-time clinical trials change drug development and patient care?

Healthcare
United States
Iniciada April 29, 2026

“For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the cloud as they occur,” writes FDA commissioner

Artículos de Fuentes

Añadir afirmación Análisis 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
3 afirmaciones para votar • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Publicado por will • Apr 29, 2026
As we consider the shift to smarter trials, we must evaluate the balance between innovation and ethical considerations. Are we prepared to address the unintended consequences that may arise from rapid changes in drug development?

Traducción pendiente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discusión
Be first to respond
Vote to see results
CLAIM Publicado por will • Apr 29, 2026
The implementation of real-time clinical trials raises important questions about regulatory oversight. How will the FDA ensure that the integrity of the data is maintained when it is continuously monitored and accessed?

Traducción pendiente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discusión
Be first to respond
Vote to see results
CLAIM Publicado por will • Apr 29, 2026
While real-time clinical trials may enhance efficiency, there are concerns about data privacy and the potential for bias in interpretation. If regulators can access data continuously, will there be sufficient safeguards to ensure that patient confidentiality is maintained?

Traducción pendiente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discusión
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us